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Objectives: The reported rate of subclinical brain injury after carotid artery stenting (CAS) seen on diffusion-weighted
magnetic resonance imaging (DWI) varies from 10% to >40%. Data from transcranial Doppler after CAS indicate that
embolization may continue for several days, suggesting that that at least some lesions seen on DWI occur postprocedure.
Because DWI lesions appear <1 hour of embolization, we used DWI to prospectively study patients before CAS, 1 hour
after, and 48 hours after CAS to answer this question.
Methods: The study participants were 48 male patients aged 59 to 83. All patients were examined by a neurologist before
and after the procedure and had DWI preprocedure and 48 hours postprocedure. In addition, 23 patients had a DWI 1
hour post-CAS. Magnetic resonance imaging exams, including axial and coronal DWI and fluid-attenuated inversion
recovery images, were read by two neuroradiologists blinded to the study timing. The embolic protection device was
obtained from all patients, washed, and the contents examined under a digital microscope for fragments >60 m.
Results: There were two periprocedural strokes and one transient ischemic attack (TIA), but no strokes or TIAs occurred
during follow-up. In the 23 patients imaged 1 hour postprocedure, new lesions were found in two (9%), and 18 (78%) had
new lesions at 48 hours (P< .001). For the entire study group, the incidence of new lesions at 48 hours was 67% (36/54).
The median number of DWI lesions was four (range, 1 to 17). Every protection device examined had atherosclerotic
debris, with a mean of 135  73 fragments (range, 18 to 310) sized >60 m and a mean of eight fragments (range,
2 to 21) sized >500 m. Findings on postprocedure DWI did not correlate with the degree of stenosis, size of
angioplasty balloon, or number of inflations, nor with the number or size of fragments retrieved from the protection
device.
Conclusions: CAS can be performed with a very low incidence of clinically evident neurologic events; however, it is
associated with embolization during and after the procedure. Protection devices effectively prevent clinical and subclinical
events during the procedure. Significant embolization continues for at least 48 hours postprocedure, causing lesions on
DWI when there is no mechanism for cerebral protection. These data correlate with transcranial Doppler reports of
continued embolization after CAS and indicate that DWI should be done as late as possible to accurately assess the rate
of subclinical brain injury with CAS procedures. ( J Vasc Surg 2007;45:867-74.)Ex vivo experiments1,2 and in vivo transcranial Doppler
(TCD) monitoring3 have shown that carotid angioplasty
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doi:10.1016/j.jvs.2006.12.058can release large numbers of plaque fragments into the
cerebral circulation. Thousands of plaque fragments were
retrieved downstream after ex vivo angioplasty, whether or
not the lesion was stented.4 To protect the brain from this
embolic barrage, carotid angioplasty is now routinely per-
formed with a sieving, or embolic protection device, placed
in the distal artery. There is concern about the degree of
protection afforded by these devices, however.5 Plaque
material may be dislodged as the device is maneuvered
through the stenotic lesion before deployment. The devices
have a pore size of approximately 100 m, a particular
concern because our ex vivo data suggest that most partic-
ulates released with angioplasty have a maximum diameter
100 m.1
TCDmonitoring of patients undergoing carotid angio-
plasty has confirmed that particulates enter the cerebral
circulation even when protection devices are in place.6
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did not correlate with new neurologic symptoms, tens to
several hundred solid emboli were detected.3,6
Because of our concern about these cerebral emboli, a
protocol was established as a collaboration between the
Vascular Surgery, Radiology, andNeurology Services when
the carotid stenting program was initiated at our facility,
the San Francisco VA Medical Center, to examine the
causes and consequences of these cerebral emboli with the
goal of reducing their number to aminimum. This required
a prospectively accumulated database, which included doc-
umenting the incidence of both clinically evident and sub-
clinical brain injury using diffusion-weighted magnetic res-
onance imaging (DWI, MRI).
Previous reports using DWI to examine subclinical
brain injury after carotid stenting have looked at only one
study postprocedure. When studies have been done 24
hours, new lesions were observed in 17% to 53% of
cases.3,7-9 Reports of DWI done at 48 hours show a trend
toward a higher incidence,10,11 possibly because of the
continued embolization seen on TCD monitoring.12 To
ensure that we included the full extent of subclinical injury
post-CAS, we initiated our series by imaging patients as late
as practical, at 48 hours. When we also observed a signifi-
cant number of new lesions on DWI at this time point, we
realized that to determine what might be done to reduce
the incidence, the first step was to clarify whether the
lesions were the result of intraprocedural or postprocedural
embolization. Therefore, a third study at 1 to 2 hours
postprocedure was added to the protocol.
METHODS
The study was done as a prospective, nonrandomized
examination of carotid angioplasty and stenting (CAS)
conducted from February 2005 through August 2006.
Patient selection was done as follows. A discussion was
undertaken with each patient by a member of the research
team or the referring practitioner about the relative risks
and benefits of CAS vs endarterectomy, which included a
review of the aortic arch and proximal carotid anatomy to
assess the feasibility of CAS. Thereafter, patients who chose
to undergo CAS were approached to participate in the
study. The study population consisted of 48 male patients
with a mean age of 71 years (range, 59 to 83 years). They
underwent 54 procedures for asymptomatic critical steno-
ses (n 25) or symptoms of transient ischemic attack (TIA;
hemispheric in 15, amaurosis fugax in 5) or cerebrovascular
accident (n  9). During the same period, nine patients
undergoing CAS either declined to participate or could not
undergo MR scanning, and 38 patients underwent carotid
endarterectomy. The protocol and consent form were ap-
proved by the Committees on Human Research at Univer-
sity of California, San Francisco, and San Francisco Veter-
ans Affairs Medical Center.
There were two phases of the protocol for identifying
new lesions onDWI. In the first 31 cases, we obtainedDWI
at 48 hours only. The procedure was then changed to
include DWI at 1 to 2 hours postprocedure and at 48 hoursin 23 cases. All 54 cases undergoing CAS and DWI are
reported.
To ensure that the lesions seen on the postprocedure
DWI were new, each subject had a study72 hours before
the procedure and postprocedure studies at 1 hour and 48
hours, as noted above (Figure 1). The DWI included axial
and coronal DWI and fluid-attenuated inversion recovery
(FLAIR) images (DWI: echoplanar spin-echo, TR/TE 
5000/100 milliseconds, b 0.500, 1,000, 20 5-mm thick
slices with a 1.5-mm gap, matrix size-128  128; FLAIR:
TR/TE/TI  8000/120/2000 milliseconds). Average
diffusion coefficients maps were calculated from the DWI
images.
The MRI studies were independently read by two
neuroradiologists (M. W. and C. G.) who were blinded to
study timing. An acute ischemic lesion was diagnosed when
it was seen on either axial or coronal DWI images and
confirmed on the corresponding average diffusion coeffi-
cients maps, or was seen on both planes of DWI. To be
considered indicative of acute injury, the lesion could not
appear on preprocedure imaging and no corresponding
FLAIR abnormality could be present for the lesion to be
considered as acute. New (acute) lesion location and size
were recorded. In cases of initial disagreement between
readers, consensus was reached by joint review of the
cases.
Every patient was examined by a neurologist, both
before and after the procedure, using the National Insti-
tutes of Health Stroke Scale.
The carotid stenting procedure was performed as fol-
lows. In addition to the DWI, a preprocedure magnetic
resonance angiography was done that included a three-
dimensional display of the aortic arch; therefore, arch an-
giography was avoided in most cases (81%). After achieving
access to the proximal thoracic aorta, a telescoping tech-
nique using the Shuttle Select Sheath (Cook, Blooming-
ton, Ind) and the JB1 (right carotid; Cook) or V-Tek (left
carotid; Cook) catheters was used to cannulate the appro-
priate great vessel.
Angiography to confirm the extracranial and intracra-
nial anatomy was performed, and the embolic protection
device was placed into the distal internal carotid artery. The
AccuNet device (Guidant, Mountain View, Calif) was used
in 51, and the Angioguard (Abbott, Abbott Park, Ill) was
used in three. Predilation angioplasty, stent deployment
(AccuLink, Guidant; or Xact, Abbott), and postdilation
angioplasty were performed (Figure 2).
After angiography to confirm satisfactory treatment of
the stenosis, the protection device was removed and com-
pletion angiograms were obtained. Periprocedural antico-
agulation consisted of pretreatment with clopidogrel in all
patients, which was continued postprocedure for 6 weeks;
intraprocedural heparin given to achieve an activated clot-
ting time of300 seconds and then continued for 12 hours
postprocedure.
An embolic protection device was used in all cases. This
was retrieved for fragment analysis in 44 cases. The col-
lapsed filter basket was rinsed with saline to remove adher-
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by washing with approximately 20 mL of saline, which was
then centrifuged, the supernatant decanted, and the frag-
ments examined at120 under a Zeiss Digital Microscope
(Carl Zeiss, Oberkochen, Germany). Photos were taken
and fragments measured and counted.With each specimen,
a sham control was also done to monitor the debris that
may have been included in the saline and glassware. This
was subtracted from the fragment count.
RESULTS
One TIA occurred and two periprocedural strokes
(stroke rate, 3.7%). One stroke occurred 6 hours after a left
internal carotid artery CAS and affected the fine motor
function of the patient’s right hand. The second occurred
after plaque fragments released during postdilation of the
stent occluded the embolic protection device, requiring
passage of a second wire and catheter to aspirate the ath-
Fig 1. Diffusion-weighted images before, 1 hour, and 4
the right hemisphere.erosclerotic debris and restore flow. The symptoms wereconfusion and a mild facial droop and were associated with
an area of brain infarction onMRI, the only infarct onMRI
in the series. In both patients symptoms had completely
resolved by their 2-week follow-up visit. There were two
myocardial infarctions, but no deaths. One femoral artery
pseudoaneurysm required thrombin injection, and two
groin hematomas requiring evacuation occurred early in
the series.
Four patients had areas of acute injury on DWI before
their carotid artery stent procedure. In the 23 cases where
DWI studies were performed 1 to 2 hours postprocedure,
only two (9%) had new lesions immediately postprocedure,
and 18 (78%) had new lesions when imaged at 48 hours
(P  .001; Table I). In the entire group there were new
lesions at 48 hours after 36 (67%) of the 54 procedures. The
median number of new lesions on DWI was four (range, 1
to 17). Most measured 1 to 2 mm in diameter, with the
largest lesion measuring 7 mm. There were new lesions
rs after carotid stenting show three small, new lesions in8 houipsilateral to the procedure in 97% of cases. In 28%, lesions
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case, there were two lesions in the contralateral hemisphere
and none ipsilateral to the CAS procedure.
When viewed with the digital microscope and the ap-
propriate sham subtractions were done, every protection
device examined had atherosclerotic fragments, with a
mean of 135 73 (range, 18 to 310) fragments sized60
m, and a mean of eight fragments (range 2 to 21) sized
500 m (Table II) (Figure 3). We examined the relation-
ship of the number and size of the fragments retrieved from
the embolic protection device with the degree of plaque
Fig 2. A, Preprocedural and B, postprocedural views of a critical
internal carotid lesion. Note the continued presence of a small area
of luminal irregularity extending outside the stent.stenosis, conduct of the procedure, and findings on post-procedureDWI. There was no correlation of the number or
size of fragments retrieved from the embolic protection
device and degree of stenosis, size of angioplasty balloon,
number of inflations, or number of new lesions on DWI.
DISCUSSION
Our data indicate that as carotid stenting is currently
practiced at our institution, nearly all embolic brain injury
occurs postprocedure. Although some late ischemic events
were expected to occur, we can only speculate why, during
a time period when thousands of plaque fragments are
released,1,3 injury to the brain is rare, while later, when the
embolic rate is considerably lower, brain injury is virtually
the norm.
Our first thought was that the embolic protection
device was highly effective. Although the pore size of the
AccuNet that was used for most our cases is 120 m, it
should entrap larger fragments that are likely to cause
ischemia.4 Furthermore, it is more effective than one might
predict in trapping fragments sized 100 m.
Second, the published TCD data gleaned from only 20
or 30 minutes of monitoring may underestimate both the
incidence and frequency of emboli postprocedure. A more
thorough examination of embolic burden after carotid
stenting will require longer periods of TCD monitoring.
Third, there could be late thrombus formation on the
stent or propagation of clot from a nonoccluding embolus
in the microvasculature. Heparin was discontinued 12
hours after the procedure, although daily clopidogrel was
prescribed for 6 weeks. We have found in an animal model
of embolic stroke that even high concentrations of heparin
have no impact on the incidence or number of brain lesions
frommicroemboli (unpublished observations), making this
explanation unlikely.
Finally, it is also unlikely that there may have been areas
of injury that were not imaged by the 1-hour postprocedure
Table I. New lesions on diffusion-weighted imaging
Group
Patients
(n)
Positive
at 1 h
Positive
at 48 h
Imagined at 54 — 36 (67%)
48 h 54 — 36 (67%)
1 h and 48 h 23 2 (9%)* 18 (78%)*
*P  .001.
Table II. Number of fragments 60 m captured in the
embolic protection device
Size (m) Mean SD
60-99 84.4 45.7
100-199 24.2 31.0
200-499 11.1 11.0
500-999 3.9 4.5
1000 1.6 2.8
Total 135.2 73.5DWI study. DWI has been shown to be positive within
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scan was done less than 1 hour after stent deployment and
postdilation angioplasty.
New lesions were seen on DWI after two of every three
CAS procedures in this series, which is nearly double the
rates reported after 24 hours.7,9,15 It is also somewhat
higher than other reports of DWI done 48 hours postpro-
cedure.10,11 Some of the difference may be technical. Most
studies report only single-plane imaging, but our DWI was
done in both the coronal and axial planes. If only the
coronal sections were read, the number of lesions was
reduced by one third, placing our data in the mid-range of
the other reported incidences. Clearly, the more complete
evaluation of brain injury performed at least 48 hours
postprocedure is to be preferred if one is examining the
incidence of new lesions on DWI.
CAS is being introduced as an alternative to carotid
endarterectomy, which rarely is accompanied by new le-
sions on DWI. We16 and others17 have shown that new
lesions are rarely seen on DWI after carotid endarterec-
tomy, and in a comparison of CAS and endarterectomy,
Roh et al18 found that both neurologic events and new
lesions on DWI were far more common with CAS.
In contrast to the incidence of subclinical injury, the
clinical outcomes in this series are comparable with carotid
endarterectomy, raising the question of the importance of
these lesions seen only on DWI. It would be naive to
reflexly respond that all brain injury is to be avoided. In the
short term, these lesions seem to have no measurable
consequences, and by 6 months post-CAS, most have
Fig 3. Debris recovered from an embolic protection
fragments above and below 100 m in size.resolved without residual effects.9Repetitive embolic injury may have a cumulative effect,
however. Recently, a link has been established between the
numbers of emboli found during TCD monitoring in pa-
tients with vascular dementia and Alzheimer disease com-
pared with nonaffected controls.19 Although much work
needs to be done to understand the mechanism of repeti-
tive emboli and dementia, it is premature to consider these
subclinical events unimportant, and until an approach is
developed that will reduce their incidence, they remain a
cause of concern.
We used a digital microscopy with 120 power to
examine the material washed from the embolic protection
devices. With this level of scrutiny, all devices contained
plaque fragments, andmany hadmaximal diameters smaller
than the device pore size. This, combined with the lack of
injury while the device is in place, seems to leave little
debate as to its utility. Even with our aggressive examina-
tion of the embolic protection devices, we could not cor-
relate fragment number or size with clinical events, or with
new lesions on DWI. Given that the emboli causing new
lesions occurred after the procedure, this lack of correlation
should be expected.
CONCLUSION
We are reporting a series of 48 patients undergoing 54
CAS procedures with excellent clinical outcomes but a
concerning number of new lesions on DWI. These subclin-
ical brain injuries did not occur during the procedure but in
the ensuing 48 hours, when transcranial Doppler studies
have confirmed an ongoing number of embolic events. We
ce. The range of sizes includes atherosclerotic tissuedevisubmit that the CAS procedure itself is safe, but new
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zation postprocedure.
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Dr Ralph Dilley (LaJolla, Calif). President Andros, members
and guests. The growing interest of using stents to treat carotid
atherosclerosis is now well documented, and the modality is being
used increasingly in many clinics and practices, often in patients
who are asymptomatic and not in high-risk categories.
Unfortunately, we are beginning to learn of a number of
potentially significant complications of carotid stenting, which
might limit the application of this intervention. For instance, a
number of recent reports have shown an increase in postprocedure
stroke risk in patients over age 80. The incidence in these reports
varies from 7% to 15%.
Second, almost all investigators agree it is important to use
protection devices to decrease the frequency of atheroemboli
during carotid stenting. These protection devices range from sim-
ple filters to the more complex flow reversal system as described by
Parodi, but skepticism remains about their efficacy in capturing
atherosclerotic particles.
In spite of these precautions, atheroemboli continue to occur
during carotid angioplasty and stenting, and now we learn from
this very nice presentation by Dr Rapp and his colleagues that
atheroembolic showers occur not only during the procedure but
continue at least up to 48 hours following the procedure when noUsing diffusion-weighted MRI, analyzed both in coronal and
axial planes, they demonstrated a 9% incidence of new lesions at 1
to 2 hours after the stent placement but also a highly significant
78% incidence at 48 hours. Most patients had multiple lesions,
most often in the treated carotid distribution. All patients in their
study had placement of a protection device during the interven-
tion, and plaque fragments were present in the 44 submitted for
analysis.
This is an excellent study and if you are concerned that these
microembolic showers, although asymptomatic at the time, may
ultimately cause problems, then the results of this study are indeed
sobering and prompt many questions about the role of carotid
stenting. I should hope the authors would comment on some of
these questions.
Were you able to correlate the incidence of new lesions with
the age of the patient? Is it likely that the embolic lesions, partic-
ularly those outside the carotid territory were related to arch
atherosclerosis with embolic debris caused by catheter manipula-
tion?
I noted that the evaluation of the arch was by MRI only in
about 80% of the cases, and I wonder if this technique is sensitive
enough to identify significant arch pathology, which if present,
might alter the treatment plan?
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any preintervention characteristics of the carotid plaque? For in-
stance, how did patients with recurrent disease as an indication
compare with de novo disease, and did you attempt to characterize
the plaque by duplex as to its degree of instability or heterogeneity
versus a stable or homogeneous plaque?
Should the workup prior to carotid stenting include trans-
esophageal echo to exclude arch pathology or duplex to evaluate
plaque characteristics, the findings of which might rule out stent-
ing as an option?
Can you elaborate a little further on what the clinical signifi-
cance of these lesions is? If they are a precursor to a dementia
syndrome and continue to embolize up to 48 hours or more, they
are very significant and a deterrent to expanding the indications for
carotid stenting.
Finally, a number of your patients in the study were asymp-
tomatic, and can you justify treating asymptomatic patients with a
stent, particularly with the findings you report today?
Again, I enjoyed this presentation and congratulate the au-
thors on an excellent study.
Dr Joseph Rapp. Thank you, Ralph. Ralph was very kind to
not comment on the extremely rough draft that I sent him the first
time around.
So do we know the timing of these lesions and could it happen
that we are just missing it and they are embolizing at the end of the
procedure and not during the procedure? Transcranial Doppler
during the procedure I think is pretty well worked out, and I do
not really understand why we do not have good data postproce-
dure because these people are monitored during the procedure in
some of these studies. We do not do transcranial Doppler. Actually
we now have a machine and we are going to start doing it for
obvious reasons that I talked about. And so I don’t know actually
the timing. My actual suspicion is that there is a lot more emboli in
the postprocedure period than we appreciate, and I think we are
going to look at that and hopefully work that out.
Does it correlate with age or the heterogeneity/homogeneity
of the plaque? Well, I hate to admit to a group of vascular surgeons
but I do not believe in homogeneity or heterogeneity of the
plaque, so we do not get it. I never have been convinced that was
worthwhile, but I knowmany of you do not share that opinion and
so you are welcome to do that study and see. We looked at every
parameter other than that that we could think of—degree of
stenosis, length of the lesion. You know we have MRI. We look at
all these lesions, and we could find nothing that correlated. We
only had 3 or 4 recurrent lesions, so it really was not worth looking
at whether they were recurrent or not. The recurrent lesions do
actually shed particles, which I was interested to find out . . .
Unidentified speaker. . . . paper was appreciated very much.
It was beautifully presented with good data, as usual. I have two
questions and a couple of comments. You mentioned that we
“don’t get emboli with carotid endarterectomy.” In fact, have you
subjected a group of patients in your institution who have under-
gone carotid endarterectomy to the same rigorous examination
with DWI as you did those undergoing angioplasty? Certainly if
you do transcranial Doppler on people that undergo CEA you see
a lot of hits in those patients, you just do not see them for long
periods of time, and while this may have been studied, I am not
aware of any literature right now to show that there are lesions
DWI after CEA unless there is an obvious complication. I am just
wondering if you happened to look at it because I think you are in
an excellent position to do that and to compare it.
Dr Rapp. We have. We published that in the Journal of
Neuroradiology in I think 2000-2001, and there is one from the
neurosurgery group in Phoenix. We found one lesion in 25 and
they found no lesions in 27 in diffusion-weighted imaging, so they
are emboli. I misspoke. I said there were no emboli. There are no
diffusion-weighted lesions after endarterectomy.
Unidentified speaker. The second question has to do
with your anticoagulant and antiplatelet regimen periprocedure.
Would you tell us a little bit about how much heparin you use,whether you use aspirin and Plavix, and when you start it and how
long you continue it?
Dr. Rapp. We keep the ACT greater than 300 during the
procedure and we continue heparin for 12 hours postop, and in the
paper, one of the other alternatives that I mention is that maybe
when you stop the heparin you are getting more emboli. We load
the patients with Plavix either by 3 days before or, rarely, we load
them the night before, depending on their proximity to us, etc. We
continue Plavix for 6 weeks. Dr Pann and I have looked at
antiplatelet agent anticoagulation in our rat model of emboli, and
I can tell you even big doses of heparin make not a wit of difference
in the incidence or the number of lesions that you get when you
embolize cholesterol crystals.
Unidentified speaker. That is exactly the point. It suggested
it is not platelet or thrombotic material that is embolizing; it is
really plaque embolization that is really critical.
Obviously papers like this, for those who are interested in
carotid endarterectomy, make our day, or at least seem to, and you
are presenting this to a group of people who are very receptive
obviously to the data that you are presenting. I would strongly
encourage you to present this again at the stroke meetings, the
American Heart Association, where you do have an eclectic audi-
ence of neurologists, neurosurgeons, vascular surgeons, etc, be-
cause they are the ones who need to hear this. There is a proposal
up right now as a tag onto the CREST trial to do neuropsychiatric
evaluations of patients in both the carotid endarterectomy as well
as in the stenting group to see whether or not there is a difference
in intellectual functioning and whether or not these DWI lesions in
fact will be forerunners of dementia. I think it is terribly important.
Whether it gets funded or not is another question. I enjoyed the
paper and congratulations.
Dr Rapp. Thank you, and, Wes, I am only trying to continue
the work that you started at the San Francisco VA.
Dr James Watson (Seattle, Wash). I, like you, do not believe
in intervening in carotid stenosis that is less than 80% unless they
are clearly symptomatic, so I would like to drill down a little more
on your definition of asymptomatic.
Before coming down here I was presented with about a 60%
carotid stenosis who had an asymptomatic Hollenhorst plaque
discovered on retinal examination. How would you manage that
patient? And as a follow-up question, what do you do with the
asymptomatic carotid stenosis with a shown stroke by CT that
shows up in your office and says they have no symptoms, but once
again has a 50% to 79% carotid stenosis? Do you treat those patients
as symptomatic or asymptomatic?
Dr Rapp. I think they are tough calls. Generally, we treat
them as asymptomatic. We treat them that we do not know when
the stroke occurred. We do not know when the Hollenhorst
plaque occurred, and they weathered the storm and they have done
well. As you know, if you have your clinical event, you are at your
highest risk of recurrent event at that time, and that risk actually
goes down and at 2 years joins the population with carotid stenosis
that has never had an event. I think if you do not know when the
event started, you are down here in this low-risk category and you
have a 60% stenosis and you are not going to do anything.
Unlike our colleagues, I just went to a (Fox-Hollow) event
and was told that we should be treating asymptomatic SFA steno-
ses, so I think there is a group of people out there who are truly
scary in their indications to do these things. As our cardiologists
have discovered that there is atherosclerosis outside the heart, this
is a problem. It is a real problem when you have one standard to do
interventions and the person down the hall has another.
Dr Jean-Pierre Becquemin (Paris, France). I really enjoyed
your paper because I think it brings new clues that thesemay not be
so innocuous that we all hoped for. I was interested to see that the
majority of events occurred later on, after deployment of the stent.
That means that you change stable plaque to unstable plaque. That
means that all the debris goes through the strut of the stents, and
my question is did you use different types of stent? Did you find a
difference between open-cell stents versus closed-cell stents?
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from a Belgium group which showed that with a closed-cell stent,
there were less emboli than with an open stent. Do you have the
same experience?
Dr Rapp. I have no experience with that. What I am inter-
ested in actually is a covered stent and there is a study looking at
covered stents in the carotid. Now that study was stopped because
of their high rate of restenosis. I have the reference in my poring
through Pub-Med to do this paper. I think that is very interesting,
but I have no data on closed or open-cell stents.
Unidentified speaker. I enjoyed your paper very much. A
couple of questions. There is some evidence experimentally at least
that you can increase the number and size of emboli by using
Dextran. Have you considered that?Unidentified speaker. Decrease, size and number, by giving
Dextran. The other question is, in light of all this then, should we
be treating these people for 3 or 4 months with high-dose statins
and antiplatelet therapy before we stent them?
Dr. Rapp.Two really great questions. I love Dextran. Using it
for years and then in the last few, I don’t know, maybe 3 or 4 years
collectively had two anaphylactic reactions to Dextran, my love of
Dextran has been tempered, but Dextran is a very good drug, and
there is a wonderful TCD paper showing that these postoperative
embolizations actually stop when they put on Dextran. I think
Dextran is exactly where we are going to go. I am concerned about
the anaphylactic reaction to it.
In terms of statins and pretreatment with statins, that is a great
idea. Certainly in our asymptomatic patients where it is unclearDr. Rapp. Increase? there is a rush to treatment that may well be a wonderful thing to try.
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